logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting.

    Article - En anglais

    Objective

    - To evaluate the cost-effectiveness of a short-course zidovudine program to prevent perinatal transmission of human immunodeficiency virus (HIV) type 1 in sub-Saharan African country settings.

    Design and Setting

    - Several clinical trials of short-course zidovudine during pregnancy for prevention of perinatal transmission of HIV are under way in developing countries in sub-Saharan Africa.

    A decision model was used to examine the cost-effectiveness of zidovudine programs in a hypothetical 1-year birth cohort in a sub-Saharan African setting from the perspective of the health care system and of society.

    A completed short course of zidovudine was assumed to reduce perinatal HIV transmission from 25% to 16.5%, approximately one half of the effect of the longer-course zidovudine.

    Estimates of program costs, lifetime HIV-related health care costs, and lost productivity costs were derived from the published literature and from preliminary data available from sites of planned clinical trials.

    Sensitivity analyses were conducted on all relevant parameters.

    Main Outcome Measures

    - Medical costs, lost productivity costs, program costs, cost savings, and incremental cost-effectiveness, expressed as cost per infant HIV infection prevented.

    Results

    - The model estimated that a national zidovudine program in a setting with 12.5% HIV seroprevalence would reduce perinatal HIV incidence by 12% (4.9 infections per 1000 births). (...)

    Mots-clés Pascal : Coût, Traitement, Prévention, Zidovudine, Infection, Virus HIV1, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Périnatal, Afrique, Etude cohorte, Economie, Nouveau né, Homme, Adulte, Essai clinique, Pyrimidine nucléoside, Antiviral

    Mots-clés Pascal anglais : Costs, Treatment, Prevention, Infection, HIV-1 virus, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Perinatal, Africa, Cohort study, Economy, Newborn, Human, Adult, Clinical trial, Pyrimidine nucleoside, Antiviral

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0352357

    Code Inist : 002B30A04B. Création : 10/04/1997.